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Abstract
Acinetobacter baumannii has emerged as a major cause of healthcare-associated infections. Controversy exists as to whether antimicrobial
resistance increases the risk of mortality. We conducted a systematic review and meta-analysis to examine this association. We searched
MEDLINE and EMBASE databases up to May 2013 to identify studies comparing mortality in patients with carbapenem-resistant
A. baumannii (CRAB) vs. carbapenem-susceptible A. baumannii (CSAB). A random-effects model was used to pool Odds Ratios (OR).
Heterogeneity was examined using I2. We included 16 observational studies. There were 850 reported deaths (33%) among the 2546
patients. Patients with CRAB had a signiﬁcantly higher risk of mortality than patients with CSAB in the pooled analysis of crude effect
estimates (crude OR = 2.22; 95% CI = 1.66, 2.98), although substantial heterogeneity was evident (heterogeneity I2 = 55%). The
association remained signiﬁcant in the pooled adjusted OR of 10 studies. Studies reported that patients with CRAB compared to patients
with CSAB were more likely to have severe underlying illness and also to receive inappropriate empirical antimicrobial treatment, which
increases the risk of mortality. Our study suggests that carbapenem resistance may increase the risk of mortality in patients with
A. baumannii infection. However, cautious interpretation is required because of the residual confounding factors and inadequate sample size
in most studies.
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Introduction
Acinetobacter baumannii causes healthcare-associated infections
(HAI), often affecting critically ill patients [1–3]. HAIs due to
A. baumannii have been associated with an increased risk of
mortality by 8% to 40% [2–4]. Of particular concern are the
prolonged survival of A. baumannii and the remarkable ability
of this pathogen to acquire resistance to multiple antibiotics
[2,5]. Rates of carbapenem resistance increased in the US from
9% in 1995 to 40% in 2004 and from 14% in 2003 to 46% in
2008 in Taiwan [1,6]. Recent studies have reported high rates
of resistance across the world, particularly in Asia-Paciﬁc and
Latin America [1,2,7,8]. Limited treatment options are
available for A. baumannii infection.
Antibiotic resistance may adversely affect clinical outcomes.
There is ongoing controversy as to whether carbapenem
resistance results in an increased risk of mortality in patients
infected with A. baumannii. Previous studies have reported
conﬂicting results. A comprehensive summary of the existing
evidence is essential for healthcare providers and policy
makers to make appropriate treatment decisions and
recommendations and to take appropriate preventive
measures. We therefore conducted a systematic review and
meta-analysis to examine the association between carbapenem
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resistance and risk of mortality in patients with A. baumannii
infection.
Methods
Search strategy and study selection
Studies were included if the authors compared mortality
in patients with carbapenem-resistant A. baumannii (CRAB)
versus carbapenem-susceptible A. baumannii (CSAB). We
excluded studies that examined only patients with either
CRAB or CSAB. We included published articles written in
English or Spanish. Letters or abstracts presented in
conferences were not included.
We searched MEDLINE and EMBASE databases up to May
2013 to identify potentially relevant studies. In addition, we
used the Cochrane library, Scielo, Cinah and Sumserach2. We
also searched the references of the potentially relevant
articles. The following search terms were used: ‘Acinetobac-
ter’ AND (‘mortality’ or ‘death’) AND (‘resistance’ or
‘carbapenem’ or ‘imipenem’ or ‘meropenem’). Two investiga-
tors (EVL and KK) independently performed systematic
literature reviews, assessed study eligibility, and extracted
information from included studies. Results for the two
reviewers were compared, with discrepancies settled through
consensus discussion.
Data extraction
We extracted information regarding study characteristics
(authors, published year, journal, country, study period, study
design and sample size), study population (mean age, mean
severity of illness, sites of infection, deﬁnition of resistance,
proportion of resistance and overall mortality rates), crude
mortality rates in patients with CRAB and in patients with
CSAB, reported crude and adjusted effect estimates, and
variables included in confounder adjustment in multivariate
analysis.
Data analysis
In the unadjusted analysis, we estimated odds ratios (OR) and
corresponding standard errors by comparing crude mortality
in patients with CRAB to that in patients with CSAB. For
multivariate analysis, we calculated standard errors from
adjusted OR and 95% conﬁdence interval (95% CI). For
studies that reported risk ratio (RR), we converted to OR.
The natural logarithms of the ORs and their corresponding
standard errors were used to pool the effect estimates across
studies using the DerSimonian and Laird random effects model
[9]. We estimated pooled crude and pooled adjusted effect
estimates. In the primary analysis for pooled adjusted effect
estimates, we included studies that reported adjusted ORs.
Several studies found no statistically signiﬁcant association in
the univariate analysis and did not report adjusted effect
estimates. Because exclusion of these studies in adjusted
pooled effect estimates could bias the results, we included
them, assuming a OR of 1 and using the standard error from
the univariate analysis for a sensitivity analysis.
Heterogeneity of ORs across studies was assessed by the
Higgins’ I2 statistic [10]. The I² statistic describes the percent-
age of variation among studies due to heterogeneity rather
than chance. To identify the potential sources of heterogene-
ity, we conducted subgroup analysis. We examined the effect
estimates by source of infection, geographic region and
deﬁnition of resistance (carbapenem or imipenem). We
conducted meta-regression analysis to examine whether effect
estimates differ signiﬁcantly by each variable. To assess the
possibility of publication bias, we visually inspected the
funnel plot for asymmetry and performed the Begg’s test and
Egger’s test [11,12]. All analyses were performed using STATA
version 11.
Results
We identiﬁed and screened 407 publications, 361 of which
were excluded after we reviewed the abstract and/or title. We
read the full text of the remaining 46 candidate articles. Thirty
articles were excluded because they were review articles
(n = 10) or duplicate publications (n = 1), did not evaluate the
outcome of interests (n = 15), or enrolled patients who did
not have CRAB or CSAB (n = 4) (Data S1). After exclusions, a
total of 16 observational studies were included in this review.
Study characteristics of the 16 included studies are
summarized in Tables 1 and 2 [13–28]. The sample size of
studies ranged from 52 to 386. The total number of patients
included in the meta-analysis was 2546, with 850 reported
deaths (33%). All studies exclusively examined patients with
Acinetobacter baumannii infections, with the exception of three
studies that included other Acinetobacter species [14,15,18]. In
cohort studies, the reported resistance to carbapenem varied
across studies, ranging from 19% to 67% (Table 1). Ten studies
examined patients with bacteraemia [14,15,17–21,23,25,26],
four studies examined all sources of infections [13,16,24,27],
and two studies examined pneumonia [22,28]. Studies were
conducted in North America (three in the USA) [13,16,21],
Asia (three in Taiwan, two in South Korea, one each in
Malaysia, Thailand and China) [14,17,19,22,23,25,26,28], Eur-
ope (two studies in Turkey and one each in the UK and
Greece) [15,18,20,24], and South America (one study in
Colombia) [27]. Among 16 studies, 13 followed the Clinical
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Laboratory Standards Institute breakpoints for A. baumannii of
imipenem and meropenem (sensitive at ≤4 lg/ml and resistant
at ≥16 lg/ml; Table 1).
The summary estimate of the 16 included studies from the
random-effects model suggested that patients with CRAB had a
signiﬁcantly higher mortality than patients with CSAB in the
univariate analysis (pooled crude OR = 2.22; 95% CI = 1.66,
2.98; Figure 1). However, effect estimates varied across studies,
with a statistically signiﬁcant heterogeneity I2 of 55%.
Ten studies reported adjusted effect estimates and adjusted
for confounding variables, such as severity of underlying
disease, co-morbidities and appropriate antimicrobial therapy
(Table 2). When we pooled the adjusted effect estimates, the
association between carbapenem resistance and mortality
remained statistically signiﬁcant (pooled adjusted OR = 2.49;
95% CI = 1.61, 3.84; I2 heterogeneity 32%; Fig. 2). Six other
studies did not report adjusted ORs. It is important to note
that four of these studies did not report adjusted RRs because
they found no statistically signiﬁcant association in the
univariate analysis or the association did not remain signiﬁcant
in multivariate analysis. For sensitivity analysis, we pooled four
of these studies (assuming adjusted OR = 1) and 10 studies
that reported adjusted ORs and found a pooled adjusted
OR = 1.77 (95% CI = 1.22, 2.55; I2 heterogeneity 50%). For
crude and adjusted effect estimates, we did not ﬁnd evidence
of publication bias in Begg’s funnel plot test (p >0.20) or
Egger’s test (p >0.20).
Because inappropriate antimicrobial treatment and severity
of underlying illness are potential confounding factors, we
assessed these variables (Table 2). Seven studies reported that
patients with CRAB were more likely to receive inappropriate
empirical antibiotic treatment than patients with CSAB.
Moreover, six studies reported that patients with CRAB were
more likely to have severe underlying illness than patients with
CSAB. As previously known, inappropriate empirical antibiotic
treatment and APACHE II score were signiﬁcant risk factors
for mortality in most studies.
We also conducted subgroup analysis using the crude
pooled estimates (Table 3). We did not observe any difference
in pooled effect estimates by geographical regions, sources of
infection or deﬁnitions of resistance.
Discussion
Acinetobacter baumannii causes healthcare-associated infec-
tions, often affecting critically ill patients. Our systematic
review and meta-analysis suggests that patients infected with
CRAB have higher mortality rates compared to patients with
CSAB in the pooled crude effect estimate. We found that the
TABLE 1. Study characteristics
First author
and Year Country Study years Data collection Source of infection Sample size
Deﬁnition of
resistance Resistance % Resistance
Cofsky 2002 [13] US 1999 Retrospective
case-control
study
Any infection (59% pneumonia) 77 NA Carbapenem NA
Kwon 2007 [14] South
Korea
2000–2005 Retrospective
matched-cohort
study
Bacteremia (36% catheter
related infection; 23%
pneumonia)
80 CLSI guidelines
2005
Imipenem NA
Wareham 2008 [15] UK 1998–2006 Retrospective
cohort study
Bacteremia (mostly catheter
related infection)
298 NA Carbapenem 18.5
Lautenbach 2009 [16] US 2001–2006 Retrospective
cohort study
Any infection or colonization 386 CLSI guidelines
2008
Imipenem 23.1
Jamulitrat 2009 [17] Thailand 2004–2007 Retrospective
cohort study
Bacteremia (45%
catheter related infection;
17% pneumonia)
198 NA Imipenem 33.8
Metan 2009 [18] Turkey 2007–2008 Prospective
cohort study
Bacteremia (29% pneumonia;
19% post-surgical wound)
100 CLSI guidelines
2005
Carbapenem 54.0
Sheng 2010 [19] Taiwan 2004–2006 Retrospective
cohort study
Bacteremia (70% catheter
related infection)
123 CLSI guidelines
2007
Carbapenem 51.2
Routsi 2010 [20] Greece 2004–2006 Prospective
cohort study
Bacteremia (51% pneumonia;
16% catheter related infection)
96 CLSI guidelines
2007
Carbapenem 31.3
Esterly 2011 [21] US 2005–2008 Retrospective
cohort study
Bacteremia 79 CLSI guidelines
2009
Carbapenem 46.8
Chang 2011 [22] Taiwan 2005–2007 Retrospective
cohort study
Ventilator-associated
pneumonia
180 CLSI guidelines Imipenem 51.7
Deris 2011 [23] Malaysia N/A Retrospective
cohort study
Bacteremia (mostly catheter
related infection)
56 CLSI guidelines Imipenem 26.8
Aydemir 2012 [24] Turkey 2005–2006 Retrospective
cohort study
Any infection (70% pneumonia) 165 CLSI guidelines
2006
Carbapenem 66.7
Huang 2012 [25] Taiwan 2002–2007 Retrospective
cohort study
Bacteremia (42% pneumonia;
10% catheter related infection)
226 CLSI guidelines
2011
Carbapenem 27.4
Kim 2012 [26] South
Korea
2007–2010 Retrospective
cohort study
Bacteremia (30% pneumonia;
25% catheter related infection)
95 CLSI guidelines
2008
Carbapenem 55.8
Lemos 2013 [27] Colombia 2006–2010 Prospective
cohort study
Any infection (35% pneumonia;
15% catheter related infection)
165 CLSI guidelines
2006
Carbapenem 63.0
Zheng 2013 [28] China 2006–2011 Retrospective
cohort study
Pneumonia 242 CLSI guidelines
2011
Carbapenem 40.1
Clinical and Laboratory Standard Institute (CLSI).
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association remained signiﬁcant in the pooled adjusted
estimate, suggesting that higher risk of death may be due to
carbapenem resistance. Similarly, previous studies of other
infections such as methicillin-resistant Staphylococcus aureus,
vancomysin-resistant Enteroccus and multidrug-resistant Pseu-
domonas aeruginosa, have also reported that drug resistance
NOTE: Weights are from random effects analysis
Overall  (I-squared = 54.7%, p = 0.005)
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FIG. 1. Crude relative risks (RRs) of mortality in adult patients with carbapenem-resistant Acinetobacter baumannii (CRAB) vs. carbapenem-
susceptible A. baumannii (CSAB).
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FIG. 2. Adjusted relative risk (RR or OR) for the association between carbapenem resistance and risk of mortality.
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may lead to increased risk of death [30–32]. However, our
ﬁndings should be interpreted with caution because of
substantial heterogeneity in effect estimates across studies
and other limitations.
Higher mortality rates found in patients with CRAB may be
due to greater severity of illness and likelihood of receiving
inappropriate empirical antibiotic treatment, which results in
increased risk of mortality. Most studies reported that patients
with CRAB were more likely to have severe underlying illness
than patients with CSAB. Moreover, carbapenem resistance is
often associated with resistance to several other classes of
antibiotics; therefore, it is difﬁcult to administer appropriate
empirical antibiotic treatment to patients with CRAB. Studies
reported that patients with CRAB were more likely to receive
inappropriate empirical antibiotic treatment. Because a num-
ber of studies did not adequately adjust for such potential
confounding factors, our ﬁndings should be interpreted with
caution. Appropriate adjustment of these potential confound-
ing factors is important in future research.
Acinetobacter baumannii has a wide spectrum of intrinsic
and acquired antibiotic resistance mechanisms. Carbapenem
resistance in A. baumannii frequently results from the pro-
duction of b-lactamases, particularly carbapenem-hydrolyzing
b-lactamases (carbapenemases) [1,2,29]. Resistance could
also result from over-expression of the efﬂux pump that
expels antibiotics and from alterations in outer membrane
porins that block the entry of antibiotics. In addition to the
ability of acquiring multiple antibiotic resistances, A. baumannii
has a number of potential virulence factors, such as
siderophore-mediated iron-acquisition systems and bioﬁlm
formation, which could possibly affect clinical outcomes
[33,34].
Our study has several limitations. It is difﬁcult to make
deﬁnitive conclusions from current evidence due to residual
confounding factors and small sample sizes in many studies.
Most studies may have lacked power to detect signiﬁcant
differences in mortality rates. It is important to examine
associations in adequately powered studies with appropriate
adjustment of confounding factors in future research. The
heterogeneity in effect estimates could also depend on
differences in study design or quality of the studies. Most
studies employed retrospective study designs, which may be
susceptible to selection bias through differential loss to follow-
up and misclassiﬁcation of survival status. Heterogeneity in the
results could be due to the small sample size in many studies
included in this analysis. Because we searched for studies
written in English or Spanish, we may have omitted studies
written in other languages.
In conclusion, our study suggests that carbapenem resistance
may increase risk of mortality in patients with A. baumannii
infection. However, cautious interpretation is required because
of the residual confounding factors by severity of illness and
inappropriate empirical antimicrobial treatment and small
sample size.
Acknowledgements
We would like to thank Liliana Raquel Lemos Luengas and Julio
Cesar Castillo Inocencio from Fundacion para el Desarrollo y
Apoyo en Salud Internacional (FUDASAI)
Transparency Declarations
Dr Lemos and Dr Kawai were Postdoctoral Research Fellows
funded by Merck & Co. Inc. The authors declares no conﬂicts
of interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Data S1. Flow chart of the search strategy and results of
mortality in adult patients with carbapenem-resistant A.
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